Journals / Journal of Clinical and Experimental Investigations / 2014 / Cilt: 5 - Sayı: 3

Effect of erythropoietin use on mean platelet volume in children undergoing chronic dialysis

Kronik diyaliz tedavisi alan çocuklarda eritropoetin kullanımının ortalama trombosit hacmine etkisi

Pages
415–419
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

J Clin Exp Invest 2014; 5 (3): 415-419

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, it was aimed to determine the relationship between erythropoietin (EPO) use and mean platelet volume (MPV) in the children undergoing dialysis.
📊
Key Findings & Data:Methods: MPV values before and after EPO use in 36 patients (16 hemodialysis - HD, 20 peritoneal dialysis PD) were retrospectively evaluated.
💡
Conclusion & Impact:J Clin Exp Invest 2014; 5 (3): 415-419
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, it was aimed to determine the relationship between erythropoietin (EPO) use and mean platelet volume (MPV) in the children undergoing dialysis. Methods: MPV values before and after EPO use in 36 patients (16 hemodialysis - HD, 20 peritoneal dialysis PD) were retrospectively evaluated. Patients were divided into two groups according to weekly EPO need as; given less than 150 U/kg defined as low EPO and more than 150 U/kg as high EPO groups. The age, weight, primary cause of chronic renal failure, dialysis methods and EPO dosages of patients were recorded. Blood samples were taken before and 4 weeks after EPO usage and MPV values were noted from complete blood counts.Results: While significant increase was seen in the MPV values after EPO in comparison to MPV values before EPO in the HD group (8.18±1.52 fL vs. 9.20±1.46 fL; p=0.046); near significant difference was found in the MPV levels after EPO (8.28±1.80 fL vs. 9.39±1.50 fL; p=0,051) in PD group. In HD patients when high dose of EPO was given, MPV levels were found to be significantly elevated (7.81 ± 1.04 vs 9.61 ± 1.05; p=0.06) after EPO. However, no difference was seen with the lowe dose EPO subgroup (8.64 ± 1.97 ve 8.67 ± 1.81; p>0,05). No effect of EPO dose was found on MPV values in PD patients (9.57 ± 1.58 ve 9.1 ± 1.42; p>0.05).Conclusion: It was observed that EPO influenced MPV values in children undergoing HD, while no effect of erythropoietin was found on MPV values of PD patients. Physicians should be careful while using high dose erythropoietin in children with high thrombosis risk. J Clin Exp Invest 2014; 5 (3): 415-419

Özet

Amaç: Bu çalışmada diyaliz uygulanan çocuklarda ortalama trombosit hacmi (OTH) ve eritropoetin (EPO) kullanımı arasındaki ilişkinin incelenmesi amaçlanmıştır. Yöntemler: Çalışmada 16 hemodiyaliz (HD), 20 periton diyalizi (PD) olmak üzere 36 hastanın eritropoetin öncesi ve sonrası OTH değerleri retrospektif olarak incelendi. Hastalar haftalık eritropoetin alımı 150 Ü/kg'ın altında (düşük EPO) ve 150 Ü/kg üzerinde (yüksek EPO) olmak üzere 2 gruba ayrıldı. Hastaların yaşları, vücut ağırlıkları, kronik böbrek yetmezliğine neden olan primer hastalıkları, uygulanan diyaliz tedavi yöntemleri, EPO dozları kaydedildi. EPO başlanmadan önce ve başlandıktan 4 hafta sonra alınan kan örneklerinde tam kan sayımı (hemogram) yapılarak OTH değerleri kaydedildi..Bulgular: Hemodiyaliz grubunun EPO sonrası OTH değerlerinde EPO öncesi OTH değerlerine göre anlamlı yükselme (8,18±1,52 fL ve 9,20±1,46 fL, p=0,046) saptanırken, PD grubunda ise EPO sonrası değerlerde yükselme olmasına rağmen, fark istatistiksel anlamlılık sınırına çok yakın bulundu (8,28±1,80 fL ve 9,39±1,50 fL, p=0,051).Yüksek dozda EPO alan HD hastalarında EPO sonrası OTH değerleri artmış olarak bulundu (7,81 ± 1,04 ve 9,61 ± 1,05 fL; p=0,06). Düşük doz EPO kullananlarda ise farklılık görülmedi (8,64 ± 1,97 ve 8,67 ± 1,81 fL; p>0,05). PD hastalarında ise EPO dozu OTH değerleri üzerinde etkili bulunmadı (9,57 ± 1,58 ve 9,10 ± 1,42 fL; p>0,05).Sonuç: HD uygulanan çocuklarda EPO'nun OTH düzeylerini etkilediği, ancak PD hastalarında OTH düzeylerinin EPO tedavisinden etkilenmediği görüldü. Hekimler tromboz riski yüksek hastalarda yüksek doz EPO kullanırken dikkatli olmalıdır

🔖

Cite This Article

BULUT, İ. K., DİNÇEL, N., YILMAZ, E., KARA, O. D., ÖZDEMİR, K., MİR, S. (2022). Effect of erythropoietin use on mean platelet volume in children undergoing chronic dialysis. Journal of Clinical and Experimental Investigations, Cilt: 5 - Sayı: 3, 415–419. https://ajindex.com/articles/561732

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Soyoral YU, Demir C, Begenik H, et al. Skin bleed- ing time for the evaluation of uremic platelet dysfunc- tion and effect of dialysis. Clin Appl Thromb Hemost 2012;18:185-188.
  2. Viron B, Chamma F, Jaar B, et al. Thrombosis of angio- access in haemodialysed patients treated with human recombinant erythropoietin. Nephrol Dial Transplant 1997;12:368-370.
  3. Tang WW, Stead RA, Goodkin DA. Effects of epoetin alfa on prohemostasis in chronic renal failure. Am J Nephrol 1998;18:263-273.
  4. Taylor JE, McLaren M, Henderson IS, et al. Prothrom- botic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant 1992;7:235-239.
  5. Cases A, Escolar G, Reverter JC, et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992;42:668- 672. Zhou XJ, Vaziri ND. Defective calcium signaling in uraemic platelets and its amelioration with long term erythropoietin therapy. Nephrol Dial Transplant 2002;17:992-997.
  6. Diaz-Ricart M, Etebanell E, Cases A, et al. Erythropoi- etin improves signaling through tyrosine phosphory- lation in platelets from uremic patients. Thromb Hae- most 1999;82:1312-1317.
  7. Thompson CB, Jakubowski JA, Quinn PG, et al. Plate- let size as a determinant of platelet function. J Lab Clin Med 1983;101:205-213.
  8. Thompson CB, Monroy RL, Skelly RR, et al. The bi- ology of platelet volume heterogeneity. In: Martin JF, Trowbridge EA, eds. Platelet heterogeneity: biology and pathology. London: Springer-Verlag; 1990:25-35.
  9. Endler G, Klimesch A, Sunder-Plassmann H, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery dis- ease. Br J Haematol 2002;117:399-404.
  10. Kılıçlı N, Demirtunç R, Konuralp C, et al. Could mean platelet volume be a predictive marker for acute myo- cardial infarction? Med Sci Monit 2005;11:387-392.
  11. Şen HS, Abakay Ö, Taylan M, et al. The importance of mean platelet volume in early mortality of pulmonary embolism. J Clin Exp Invest 2013;4:298-301.
  12. Yılmaz N, Özkan OV, Büyükbaş S, et al. Mean platelet volume in patients with acute pancreatitis. J Clin Exp Invest 2011;2:362-365.
  13. Sharpe PC, Desai ZR, Morris TCM. Increase in mean platelet volume in patients with chronic renal failure treated with erythropoietin. J Clin Pathol 1994;47:159- 161. Erçoban HS. Kronik böbrek yetmezliğinde ortalama trombosit hacmini etkileyen faktörler ve klinik önemi. Yan dal uzmanlık tezi. Başkent Üniversitesi Pediatrik Nefroloji Bilim Dalı, 2008. Dow RB. The clinical and la